Trials / Completed
CompletedNCT02663973
Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,000 (actual)
- Sponsor
- Latin American Cooperative Oncology Group · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The principal goal of this study is to describe the epidemiology of breast cancer in the Brazilian population
Detailed description
The principal goal of this study is to describe the epidemiology of breast cancer in the Brazilian population. Other specific goals are: * To evaluate the demographic and socio-demographic profile, comorbidities and reproductive risks, anthropometric profile and family history. * Characterize the breast tumors immunophenotype through anatomopathological data, such as: tumor grade, estrogen receptor, progesterone receptor, HER2, Ki67. * Describe the screening tests, main symptoms and cancer stage in the moment of the diagnosis. * Describe the initial cancer treatment and locally advanced such as surgery, radiotherapy, chemotherapy and endocrine therapy. * Describe palliative treatment for recurrent or metastatic breast cancer: chemotherapy, radiotherapy, biphosphonate, and others. * Evaluate the clinical outcomes such as: local or diffuse relapse, period of time until progression to metastatic cancer, global lifespan and specific breast cancer lifespan. * Evaluate clinical complications of the metastatic disease, such as: brain metastasis, spinal cord compression, skeletal related events. * Analyze the demographical and socio-economical characteristics, clinical-pathological characteristics of the tumor, treatment, clinical outcomes, type of institution (private/public), and other factors that may impact clinical outcome.
Conditions
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2020-06-15
- Completion
- 2021-04-01
- First posted
- 2016-01-26
- Last updated
- 2021-06-15
Locations
24 sites across 1 country: Brazil
Source: ClinicalTrials.gov record NCT02663973. Inclusion in this directory is not an endorsement.